146 related articles for article (PubMed ID: 7962650)
21. Cytoplasmic expression of c-erb-B2 in endometrial carcinomas.
Lambropoulou M; Stefanou D; Alexiadis G; Tamiolakis D; Tripsianis G; Chatzaki E; Vandoros GP; Kiziridou A; Papadopoulou E; Papadopoulos N
Onkologie; 2007 Oct; 30(10):495-500. PubMed ID: 17890888
[TBL] [Abstract][Full Text] [Related]
22. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.
Biesterfeld S; Veuskens U; Schmitz FJ; Amo-Takyi B; Böcking A
Anticancer Res; 1996; 16(5A):2497-500. PubMed ID: 8917341
[TBL] [Abstract][Full Text] [Related]
23. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands.
Gibbons MD; Manne U; Carroll WR; Peters GE; Weiss HL; Grizzle WE
Laryngoscope; 2001 Aug; 111(8):1373-8. PubMed ID: 11568571
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis.
Hilbe W; Dirnhofer S; Oberwasserlechner F; Eisterer W; Ammann K; Schmid T; Hilbe G; Thaler J; Wöll E
J Clin Pathol; 2003 Oct; 56(10):736-41. PubMed ID: 14514775
[TBL] [Abstract][Full Text] [Related]
25. Expression of epidermal growth factor receptor in breast carcinoma.
Lewis S; Locker A; Todd JH; Bell JA; Nicholson R; Elston CW; Blamey RW; Ellis IO
J Clin Pathol; 1990 May; 43(5):385-9. PubMed ID: 2370306
[TBL] [Abstract][Full Text] [Related]
26. Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.
Cooper WA; Russell PA; Cherian M; Duhig EE; Godbolt D; Jessup PJ; Khoo C; Leslie C; Mahar A; Moffat DF; Sivasubramaniam V; Faure C; Reznichenko A; Grattan A; Fox SB
Clin Cancer Res; 2017 Aug; 23(16):4569-4577. PubMed ID: 28420726
[No Abstract] [Full Text] [Related]
27. Estimation of maspin's subcellular localization in invasive ductal breast cancer via light microscopy and computerized image analysis: a comparative study.
Panou M; Kavantzas N; Sergentanis T; Sakellariou S; Agrogiannis G; Chatzipantelis P; Anastasopoulou E; Soranoglou V; Zagouri F; Korkolopoulou P; Patsouris E; Bramis I; Zografos GC
J BUON; 2013; 18(2):342-51. PubMed ID: 23818344
[TBL] [Abstract][Full Text] [Related]
28. A testing algorithm for determination of HER2 status in patients with breast cancer.
Nichols DW; Wolff DJ; Self S; Metcalf JS; Jacobs D; Kneuper-Hall R; Cate JC
Ann Clin Lab Sci; 2002; 32(1):3-11. PubMed ID: 11848614
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer.
Platt-Higgins AM; Renshaw CA; West CR; Winstanley JH; De Silva Rudland S; Barraclough R; Rudland PS
Int J Cancer; 2000 Mar; 89(2):198-208. PubMed ID: 10754500
[TBL] [Abstract][Full Text] [Related]
30. Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment.
Koens L; van de Ven PM; Hijmering NJ; Kersten MJ; Diepstra A; Chamuleau M; de Jong D
Histopathology; 2018 Sep; 73(3):473-482. PubMed ID: 29758590
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
Sharma BK; Ray A; Kaur S; Gupta S
Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
[TBL] [Abstract][Full Text] [Related]
32. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
[TBL] [Abstract][Full Text] [Related]
33. Analysis of membranous Ki-67 staining in breast cancer and surrounding breast epithelium.
Cserni G
Virchows Arch; 2018 Aug; 473(2):145-153. PubMed ID: 29594352
[TBL] [Abstract][Full Text] [Related]
34. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa.
Gunia S; Kakies C; Erbersdobler A; Koch S; May M
J Clin Pathol; 2012 Aug; 65(8):715-20. PubMed ID: 22554964
[TBL] [Abstract][Full Text] [Related]
35. HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4.
Tovey SM; Dunne B; Witton CJ; Cooke TG; Bartlett JM
Breast Cancer Res; 2006; 8(2):R19. PubMed ID: 16606438
[TBL] [Abstract][Full Text] [Related]
36. Expression of c-erbB-2 gene in human head and neck carcinoma.
Craven JM; Pavelic ZP; Stambrook PJ; Pavelic L; Gapany M; Kelley DJ; Gapany S; Gluckman JL
Anticancer Res; 1992; 12(6B):2273-6. PubMed ID: 1363518
[TBL] [Abstract][Full Text] [Related]
37. C-erbB-2 expression in squamous cell carcinoma of the head and neck.
Field JK; Spandidos DA; Yiagnisis M; Gosney JR; Papadimitriou K; Stell PM
Anticancer Res; 1992; 12(3):613-9. PubMed ID: 1377893
[TBL] [Abstract][Full Text] [Related]
38. Immunocytochemical localization of c-erbB-2 protein in transitional cell carcinoma of the urinary bladder.
Coombs LM; Oliver S; Sweeney E; Knowles M
J Pathol; 1993 Jan; 169(1):35-42. PubMed ID: 8094432
[TBL] [Abstract][Full Text] [Related]
39. Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible.
Kaye PV; Ilyas M; Soomro I; Haider SA; Atwal G; Menon S; Gill S; Richards C; Harrison R; West K; Ragunath K
Histopathology; 2016 Sep; 69(3):431-40. PubMed ID: 26918780
[TBL] [Abstract][Full Text] [Related]
40. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
